VV GMCSF Lact
Alternative Names: Double Recombinant Vaccinia Virus VV-GMCSF-Lact; VV-GMCSF-LactLatest Information Update: 24 May 2022
At a glance
- Originator Institute of Chemical Biology and Fundamental Medicine; Oncostar; State Research Center of Virology and Biotechnology
- Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies; Oncolytic viruses; Proteins
- Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunologic cytotoxicity; Lactapin expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
- Preclinical Glioblastoma
Most Recent Events
- 11 May 2022 Phase-I clinical trials in Breast cancer (Recurrent, Refractory metastatic disease) in Russia (Intratumoural) (NCT05376527)
- 14 Oct 2021 Preclinical trials in Glioblastoma in Russia (Intratumoural) before October 2021
- 14 Oct 2021 Preclinical trials in Glioblastoma in Russia (IV) before October 2021